Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 12/20 | 0.70 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.61 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10990802 | 0.94 | KCNA3 (0.71) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL7381285 | 0.92 | KCNA3 (0.69) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL10525295 | 0.92 | KCNA3 (0.69) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL1900320 | 0.92 | HTR1B (0.67) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL2177350 | 0.90 | HTR1B (0.78) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL9770352 | 0.90 | KCNA3 (0.81) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902840 | 0.88 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902854 | 0.88 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902853 | 0.88 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D | |
| SCHEMBL16902852 | 0.88 | KCNA3 (0.79) | HTR1BKCNA3SLC6A4HRH1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2018-07-31 | — | — | US | disclosed |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2017-11-09 | — | — | US | disclosed |
| US-9687478-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2017-06-27 | — | — | US | disclosed |
| US-RE46417-E1 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands | ALMIRALL, S.A. (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2016-10-13 | — | — | US | disclosed |
| US-9333195-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2016-05-10 | — | — | US | disclosed |
| US-20150246026-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA, S.A. (ES) | 2015-09-03 | — | — | US | disclosed |
| EP-1200431-B3 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL SA (ES) | 2015-06-24 | — | — | EP | disclosed |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-09-22 | — | — | US | disclosed |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-07-08 | — | — | US | disclosed |
| US-6750226-B2 | FOR MANUFACTURE OF MEDICAMENT FOR USE IN THERAPY OF RESPIRATORY, URINARY OR GASTROINTESTINAL DISEASE | ALMIRALL-PRODESFARMA, S.A. (ES) | 2004-06-15 | — | — | US | disclosed |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2004-04-15 | — | — | US | disclosed |
| EP-1353919-A2 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2003-10-22 | — | — | EP | disclosed |
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | ALMIRALL, S.A. (ES) | 2003-03-20 | — | — | US | disclosed |
| WO-2002053564-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-11 | — | — | WO | disclosed |
| EP-1200431-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | Almirall Prodesfarma, S.A. (ES) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001004118-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | ALMIRALL PRODESFARMA S.A. (ES) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034867-B2 | Quinuclidine derivatives and medicinal compositions containing the same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | HTR1B 851/4885KCNA3 460/4885SLC6A4 1296/4885 |
| US-20160296503-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO2, CHRM3 | HTR1B 1441/4885KCNA3 609/4885SLC6A4 2619/4885 |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | CHRM3, CBR1, CHRNB1 | HTR1B 177/4885KCNA3 940/4885SLC6A4 1263/4885 |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | NR3C2, NR3C1, NR4A3 | HTR1B 1273/4885KCNA3 463/4885SLC6A4 429/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | HTR1B 320/4885KCNA3 1179/4885SLC6A4 3289/4885 |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | NR1H4, CHRM3, CHRM4 | HTR1B 447/4885KCNA3 861/4885SLC6A4 494/4885 |
| US-20040072863-A1 | Novel quinuclidine derivatives and medicinal compositions containing the same | CYP11B1, CYP3A7, CBR1 | HTR1B 462/4885KCNA3 2142/4885SLC6A4 1494/4885 |
| US-20170319557-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM3, OPRD1 | HTR1B 902/4885KCNA3 421/4885SLC6A4 1154/4885 |
| US-20150246026-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NR4A1, CHRM4, NR4A3 | HTR1B 1332/4885KCNA3 738/4885SLC6A4 701/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | HTR1B 281/4885KCNA3 826/4885SLC6A4 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.